A Clinical Evaluation of the Tension-Free Vaginal Tape Obturator System For Treatment of Stress Urinary Incontinence (Urinary Leakage)

NCT ID: NCT00196521

Last Updated: 2007-12-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Stress urinary incontinence affects nearly 30 million women worldwide and the main goal of surgical treatment is to stop urinary incontinence (urinary leakage) that occurs with physical activity, coughing, sneezing, etc.Patients in the study will have an operation to improve urinary incontinence symptoms. This will involve inserting a mesh sling to help support the urethra (tube leading into your bladder). During the operation, the study doctor will use tension-free vaginal obturator system. The study will include women diagnosed with Stress Urinary Incontinence who have completed their families.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stress Urinary Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tension-free vaginal tape obturator system

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has objective demonstrable signs of stress urinary incontinence (SUI), including patients with ISD. Objective testing includes: standing stress test, urodynamics evaluation, or pad test.
* Patient is age 18 or older.
* Patient had a hysterectomy, tubal ligation or is otherwise incapable of pregnancy, or had a negative pregnancy test prior to study entry and has decided to cease childbearing.
* Patient agrees to participate in the study, including completion of all study-related procedures and evaluations, and documents this agreement by signing the IRB/EC-approved informed consent.

Exclusion Criteria

* Patient has an associated or suspected neurological disease.
* Patient is on anti-coagulation therapy.
* Patient has received an investigational drug or device in the past 60 days.

For patients having URP measurements at selected sites:

* Patient has an active lesion or present injury to perineum or urethra.Patient has a urethral obstruction.
* Patient has an unreduced cystocele \> Stage 1. (Reduction of prolapse prior to URP testing is required.) Reduction of Cystocele (if applicable). Patients should be seated in a semi-fowler's position with head of bed at 40-60 degrees.

Carefully place a half of a speculum into the vagina, reducing prolapse to less than stage 1. Be careful not to over extend or elongate the vaginal length.

The half of a speculum must be placed with pressure emphasis on the posterior and apical areas. Anterior wall pressure or urethral pressure must be avoided at all times.

* The subject has active infection upon urine dipstick analysis, defined as ≥+1 leukocytes or ≥+1 nitrates (Must reschedule appointment after UTI resolves.)
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ethicon, Inc.

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martin Weisberg, MD

Role: STUDY_DIRECTOR

Ethicon, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Urogynecology Associates of CO

Denver, Colorado, United States

Site Status

Bladder Control Center

Norwalk, Connecticut, United States

Site Status

Urogynecology Specialists of Kenuckiana

Louisville, Kentucky, United States

Site Status

Greater Baltimore Medical Center

Baltimore, Maryland, United States

Site Status

Oakwood Hospital

Dearborn, Michigan, United States

Site Status

Sheldon Freedman, MD

Las Vegas, Nevada, United States

Site Status

St. Peter's University Hospital

New Brunswick, New Jersey, United States

Site Status

The Institute for Female Pelvic Medicine & Reconstructive Surgery

Allentown, Pennsylvania, United States

Site Status

University Urology

Knoxville, Tennessee, United States

Site Status

McDonlad Murrmann Women's Clinic

Memphis, Tennessee, United States

Site Status

Sound Urology Ambulatory Surgery Center

Edmonds, Washington, United States

Site Status

Sunnybrook & Women's College Health Sciences Center

Toronto, Ontario, Canada

Site Status

Service d'Urologie

Marseille, , France

Site Status

Hopital Des Diaconesses

Paris, , France

Site Status

Klinikum der Eberhard-Karls-Universität

Tübingen, , Germany

Site Status

Women's and Children's Hospital

Singapore, , Singapore

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

University of Ulsan College of Medicine and Asan Medical Center

Seoul, , South Korea

Site Status

Southport District General Hospital

Southport, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada France Germany Singapore South Korea United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

300-04-004

Identifier Type: -

Identifier Source: org_study_id